Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Trial Details

NCT ID
NCT06686394
Phase
PHASE1 / PHASE2
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Patritumab deruxtecan
  • Trastuzumab
  • Trastuzumab Biosimilar
  • Pertuzumab
  • Tucatinib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Kingston, Ontario, Canada|44.22976,-76.48098

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, an…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →